Aspire Biopharma Holdings (ASBP) Free Cash Flow (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Free Cash Flow for 6 consecutive years, with -$2.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Free Cash Flow fell 85.53% year-over-year to -$2.1 million in Q2 2026; TTM through Jun 2026 was -$7.2 million, a 147.12% decrease from a year earlier, with the FY2025 full-year figure at -$4.9 million, down 1214.54% from the prior year.
• Free Cash Flow was -$2.1 million for Q2 2026 at Aspire Biopharma Holdings, up from -$3.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $479569.0 in Q4 2024 and troughed at -$3.0 million in Q1 2026.
• A 5-year average of -$689153.5 and a median of -$191461.0 in 2023 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow soared 407.16% in 2024 and plunged 1927.43% in 2025, its largest moves.
• Over 5 years, Free Cash Flow stood at -$35870.0 in 2022, then plunged by 335.26% to -$156128.0 in 2023, then soared by 407.16% to $479569.0 in 2024, then tumbled by 293.47% to -$927841.0 in 2025, then slumped by 128.02% to -$2.1 million in 2026.
• The last three Free Cash Flow figures came in at -$2.1 million (Q2 2026), -$3.0 million (Q1 2026), and -$927841.0 (Q4 2025), per Business Quant data.